Cell-penetrating d-Isomer Peptides of p53 C-terminus: Long-term Inhibitory Effect on the Growth of Bladder Cancer

Urology

Volumn 75, Issue 4, 2010, Pages 813-819

  Araki, Daiji ^a   Takayama, Kentaro ^c   Inoue, Miyabi ^a   Watanabe, Toyohiko ^a   Kumon, Hiromi ^a   Futaki, Shiroh ^c   Matsui, Hideki ^a   Tomizawa, Kazuhito ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; D11R P53C' RIHA2; DFHV P53C' RIHA2; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; POLYARGININE; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL STRAIN; CELL STRAIN J82; CELL SURVIVAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG SYNTHESIS; FEMALE; FLOCK HOUSE VIRUS; HUMAN; HUMAN CELL; ISOMER; MOUSE; NODAVIRUS; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL RATE;

ANIMALS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; MICE; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 77950298119     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.10.002     Document Type: Article

References (30)

1. Al-Sukhun S., and Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 8 (2003) 2064-2075
2. Werthman P.E., Drazan K.E., Rosenthal J.T., et al. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 155 (1996) 753-756
3. Verma I.M., and Somia N. Gene therapy-promised, problems and prospects. Nature 389 (1997) 239-242
4. McCormick F. Cancer gene therapy: fringe or cutting edge. Nat Rev Cancer 1 (2001) 130-141
5. El-Andaloussi S., Holm T., and Langel U. Cell-penetrating peptides: mechanisms and applications. Curr Pharm Des 11 (2005) 3597-3611
6. Gupta B., Levchenko T.S., and Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57 (2005) 637-651
7. Wadia J.S., and Dowdy S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57 (2005) 579-596
8. Futaki S., Suzuki T., Ohashi W., et al. Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276 (2001) 5836-5840
9. Vives E., Brodin P., Lebleu B., et al. HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272 (1997) 16010-16017
10. Suzuki T., Futaki S., Niwa M., et al. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 277 (2002) 2437-2443
11. Wadia J.S., Stan R.V., and Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10 (2004) 310-315
12. Takenobu T., Tomizawa K., Matsushita M., et al. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 1 (2002) 1043-1049
13. Inoue M., Tomizawa K., Matsushita M., et al. p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells. Eur Urol 49 (2006) 161-168
14. Han X., Bushweller J.H., Cafiso D.S., et al. Membrane structure and fusion-triggering conformational change of the fusion domain from influenza hemagglutinin. Nat Struct Biol 8 (2001) 715-720
15. Skehel J.J., Cross K., Steinhauer D., et al. Influenza fusion peptides. Biochem Soc Trans 29 (2001) 623-626
16. 2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem 280 (2005) 8285-8289
17. Michael D., and Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13 (2003) 49-58
18. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4 (2004) 793-805
19. Olsson A., Manzl C., Strasser A., et al. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?. Cell Death Differ 14 (2007) 1561-1575
20. Hupp T.R., Sparks A., and Lane D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83 (1995) 237-245
21. Snyder E.L., Meade B.R., Saenz C.C., et al. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2 (2004) 186-193
22. Futaki S., Kiwada T., and Sugiura Y. Control of peptide structure and recognition by Fe(III)-induced helix destabilization. J Am Chem Soc 126 (2004) 15762-15769
23. Futaki S., and Kitagawa K. Peptide-unit assembling using disulfide cross-linking: a new approach for construction of protein models. Tetrahedron Lett 35 (1994) 1267-1270
24. Wu H.Y., Tomizawa K., Oda Y., et al. Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. J Biol Chem 279 (2004) 4929-4940
25. Pfister C., Flaman J.M., Dunet F., et al. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. J Urol 162 (1999) 69-73
26. Werthman P.E., Drazan K.E., Rosenthal J.T., et al. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 155 (1996) 753-756
27. Chester J.D., Kennedy W., Hall G.D., et al. Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo. Gene Ther 10 (2003) 172-179
28. Siemens D.R., Crist S., Austin J.C., et al. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model. J Urol 170 (2003) 979-984
29. Li Y., Pong R.C., Bergelson J.M., et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59 (1999) 325-330
30. Sachs M.D., Rauen K.A., Ramamurthy M., et al. Integrin alpha (v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 60 (2002) 531-536